ΠΑΝΕΛΛΗΝΙΟ ΟΦΘΑΛΜΟΛΓΙΚΟ ΣΥΝΕΔΡΙΟ  2012

DEXAMETHASONE INTRAHYLOIDAL INJECTION FOR TREATMENT OF DIABETIC MACULAR EDEMA

​

  Athens naval hospital

​

OBJECTIVE:

To evaluate intravitreal injection of dexamethasone 0.4 mg in patients presenting with diabetic macular edema in terms of central macular thickness and visual acuity (BCVA).

 

METHOD:

 

25 eyes were selected without any previous treatment with central macular foveal thickness >500μm and visual acuity < 2/10. 10 IU dexamethasone 0.4 mg was administered Followed by argon laser (grid, panretinal) over 4 months +/- 1

 

RESULTS:

An improvement in central macular thickness to 230 µm and visual acuity of 5/10 on average was observed. The reduction in central foveal thickness occurred after day 7 of infusion and was maintained until month 4. No improvement in vitrectomy eyes No patient had an increase in intraocular pressure (IOP) which averaged 18 mmHg.

 

CONCLUSION:

 

It appears that intravitreal dexamethasone infusion is therapeutic in reducing diabetic macular edema. To further confirm the results, the study should be made more extensive with a larger number of witnesses and a longer follow-up time.